AI-Led Drug Discovery Gains Industrial Scale as Strategic Alliance Reshapes Pharmaceutical Innovation
The pharmaceutical industry is entering a decisive phase where artificial intelligence is no longer a peripheral tool but a central driver of how new medicines are discovered, developed, and commercialized. The $2.75 billion agreement between Eli Lilly and Insilico Medicine illustrates a structural shift in how global drug pipelines are being built. Rather than relying…









